Generation Bio

Generation Bio SG&A Expenses

Delisted

The Selling, General & Administrative Expenses of Generation Bio (GBIO) as of Nov 10, 2026 is 37.78 M USD. In the previous year, Selling, General & Administrative Expenses was 50.85 M USD — a change of -25.70% (lower).

SG&A Expenses

37.78 MUSD

YoY

-25.70%

Last updated:

Selling, General & Administrative Expenses of Generation Bio is 2024 37.78 M USD. Selling, General & Administrative Expenses of Generation Bio was 2023 50.85 M USD. It decreases by -25.70% lower compared to the previous year.

The Generation Bio SG&A Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SG&A Expenses
Date
SG&A Expenses
Jan 1, 2018
9.18 M USD
Jan 1, 2019
12.17 M USD
Jan 1, 2020
22.58 M USD
Jan 1, 2021
33.85 M USD
Jan 1, 2022
44.46 M USD
Jan 1, 2023
50.85 M USD
Jan 1, 2024
37.78 M USD
The Generation Bio SG&A Expenses history
YEARSG&A ExpensesYoY
37.78 MUSD-25.70%
50.85 MUSD+14.36%
44.46 MUSD+31.34%
33.85 MUSD+49.92%
22.58 MUSD+85.59%
12.17 MUSD+32.58%
9.18 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

Selling, General & Administrative Expenses of Generation Bio is 37.78 M USD in 2024.

Selling, General & Administrative Expenses of Generation Bio changed from 50.85 M USD to 37.78 M USD, representing a -25.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Selling, General & Administrative Expenses Generation Bio since 2006 – with annual values, charts, and detailed analysis.

SG&A expenses include all non-production costs such as salaries, marketing, rent, and administrative overhead. They are a key component of operating expenses.

Selling, General & Administrative Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Selling, General & Administrative Expenses's Generation Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Generation Bio

All Key Metrics — Generation Bio